Aurinia Pharmaceuticals (AUPH) Misses Q1 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights
May 6, 2021 4:05 PM EDT- Quarter highlights include FDA approval, launch and early market penetration of LUPKYNIS as the first approved oral therapy for lupus nephritis (LN) -
- Over 250 patient start forms received by the end of the first quarter -
- Cash and cash equivalents, and investments of $360.9 million at March 31, 2021 -
- Conference call to be hosted today at 5:00 p.m. ET -
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the... More
